ImmuCell reports record Q1 2024 sales of $7.3M, up 111% YoY

IMMUCELL CORP /DE/

2024-Q1 EPS reported -$0.06 revenue$7,257,577

Total sales for Q1 2024: $7.3M, 111% increase from $3.4M in Q1 2023.
Trailing twelve-month sales ended Mar 31, 2024: $21.3M, up 33% from $16.0M.
Backlog of orders $9.1M at Mar 31, 2024, down from $9.4M Dec 2023 but up from $2.5M Dec 2022.
Company expects FDA response on Re-Tain CMC Technical Section by May 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUCELL CORP /DE/ reported Q1 2024 results: revenue $ 7.3 million.

Period: Q1 2024
Revenue: $ 7.3 million
Result: preliminary results

Exact text from the filing

first quarter of 2024, which ended March 31, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-Month Periods Ended March 31, $ 7.3 million $ 3.4 million $ 3.8 million 111 % During the Twelve-Month Periods Ended March 31, $ 21.3 million $ 16.0 million $ 5.3 million 33 % Total sales during the three-month period ended

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUCELL CORP /DE/ filing history →

Source: SEC EDGAR

accession 0001213900-24-031589

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.